{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T11:02:09Z","timestamp":1762340529086,"version":"build-2065373602"},"reference-count":15,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Neurology and Neurosurgery"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1016\/j.clineuro.2012.04.027","type":"journal-article","created":{"date-parts":[[2012,5,29]],"date-time":"2012-05-29T15:01:29Z","timestamp":1338303689000},"page":"165-169","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Bevacizumab as salvage therapy for progressive brain stem gliomas"],"prefix":"10.1016","volume":"115","author":[{"given":"T.","family":"Reithmeier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.O. Contreras","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.S.","family":"Spehl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Mader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Nikkhah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.O.","family":"Pinsker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clineuro.2012.04.027_bib0005","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11060-008-9782-3","article-title":"Bevacizumab and irinotecan treatment for progressive diffuse brainstem glioma: case report","volume":"93","author":"Torcuator","year":"2009","journal-title":"Journal of Neuro-Oncology"},{"key":"10.1016\/j.clineuro.2012.04.027_bib0010","article-title":"Treatment of progressive brain stem glioma with bevacizumab: radiological, metabolic and histopathological aspects","author":"Reithmeier","year":"2011","journal-title":"Central European Neurosurgery"},{"key":"10.1016\/j.clineuro.2012.04.027_bib0015","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1093\/brain\/124.12.2528","article-title":"Brainstem gliomas in adults: prognostic factors and classification","volume":"124","author":"Guillamo","year":"2001","journal-title":"Brain"},{"key":"10.1016\/j.clineuro.2012.04.027_bib0020","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00415-008-0589-0","article-title":"Natural history and management of brainstem gliomas in adults. A retrospective Italian study","volume":"255","author":"Salmaggi","year":"2008","journal-title":"Journal of Neurology"},{"key":"10.1016\/j.clineuro.2012.04.027_bib0025","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s11060-005-9097-6","article-title":"Mechanisms of angiogenesis in gliomas","volume":"78","author":"Kargiotis","year":"2006","journal-title":"Journal of Neuro-Oncology"},{"key":"10.1016\/j.clineuro.2012.04.027_bib0030","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1200\/JCO.2008.16.3055","article-title":"Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma","volume":"27","author":"Kreisl","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.clineuro.2012.04.027_bib0035","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1212\/01.wnl.0000304121.57857.38","article-title":"Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence","volume":"70","author":"Norden","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.clineuro.2012.04.027_bib0040","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s11060-008-9745-8","article-title":"An exploratory survival analysis of anti-angiogenic therapy forrecurrent malignant glioma","volume":"92","author":"Norden","year":"2009","journal-title":"Journal of Neuro-Oncology"},{"key":"10.1016\/j.clineuro.2012.04.027_bib0045","article-title":"Advantages of high b-value diffusion-weighted imaging to diagnose pseudo-response in patients with recurrent glioma after bevacizumab treatment","author":"Yamasaki","year":"2011","journal-title":"European Journal of Radiology"},{"key":"10.1016\/j.clineuro.2012.04.027_bib0050","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","article-title":"Update response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group","volume":"28","author":"Wen","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.clineuro.2012.04.027_bib0055","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3171\/2008.4.17492","article-title":"Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival","volume":"110","author":"Narayana","year":"2009","journal-title":"Journal of Neurosurgery"},{"key":"10.1016\/j.clineuro.2012.04.027_bib0060","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ijrobp.2010.01.055","article-title":"Prognostic value of early [18F]fluoroethyltyrosine positron emission tomography after radiochemotherapy in glioblastoma multiforme","volume":"80","author":"Piroth","year":"2011","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.clineuro.2012.04.027_bib0065","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11060-008-9526-4","article-title":"The positive predictive value of O-(2-[18F]fluoroethyl)-l-tyrosine (FET) PET in the diagnosis of a glioma recurrence after multimodal treatment","volume":"88","author":"Mehrkens","year":"2008","journal-title":"Journal of Neuro-Oncology"},{"key":"10.1016\/j.clineuro.2012.04.027_bib0070","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1007\/s00259-007-0534-y","article-title":"for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading","volume":"34","author":"P\u00f6pperl","year":"2007","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"key":"10.1016\/j.clineuro.2012.04.027_bib0075","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1215\/15228517-2008-071","article-title":"Colon perforation during antiangiogenic therapy for malignant glioma","volume":"11","author":"Norden","year":"2009","journal-title":"Neuro-Oncology"}],"container-title":["Clinical Neurology and Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846712002569?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846712002569?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T14:29:14Z","timestamp":1759588154000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0303846712002569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S0303846712002569"],"URL":"https:\/\/doi.org\/10.1016\/j.clineuro.2012.04.027","relation":{},"ISSN":["0303-8467"],"issn-type":[{"type":"print","value":"0303-8467"}],"subject":[],"published":{"date-parts":[[2013,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bevacizumab as salvage therapy for progressive brain stem gliomas","name":"articletitle","label":"Article Title"},{"value":"Clinical Neurology and Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clineuro.2012.04.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}